Published in Cardiovascular Business Week, February 23rd, 2010
Initiated the first Phase III trial of Stedivaze, a potential best-in-class coronary vasodilator for cardiac stress testing
Increased FAMILION® genetic testing gross revenue by 25% and improved gross margins from 35% to 53%, over the same period a year...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.